1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Session

$Thumbnail for OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)$

MM - 1078

OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Thomas S. Lin

Poster Presenter: Thomas S. Lin

Video

Thumbnail for Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?

AML - 1079

Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?

Aakriti Adhikari

SOHO 2026 Annual Meeting

Posters by Session

OPTec/OPTal: A Phase 2 study to evaluate outpatient (OP), step-up administration of teclistamab (Tec) or talquetamab (Tal) with prophylactic tocilizumab (prophyToci) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Pretransplant Measurable Residual Disease and Survival After Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: Does Donor Type Change the Risk?

Fludarabine/Melphalan Versus Fludarabine/Busulfan Conditioning in AML Undergoing Allogeneic HCT

Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships

Sex-Based Disparities in Resource Utilization and Complications in Patients Hospitalized with Aggressive B-Cell Non-Hodgkin Lymphoma: A National Inpatient Analysis 2019-2020

Projections of Mortality rates in Hematologic Malignancies Among Older Adults: A Centers for Disease Control and Prevention WONDER Database Analysis Through 2035

Validation of an FLT3 Activity Signature to Predict FLT3 Inhibitor Response in Acute Myeloid Leukemia

GLP-1 Receptor Agonists and Venous Thromboembolism Risk in Multiple Myeloma

Ninety-Day Readmissions After Hematopoietic Stem Cell Transplantation: A Nationwide Comparative Analysis of Oncologic and Nononcologic Indications